Last Updated: 4/1/2011
|Carey Anders, M.D.
Dr. Anders is board-certified in both Internal Medicine and Medical Oncology. Her clinical interest is in breast cancer, specifically breast cancer arising in younger women and those who have developed brain metastasis.
Dr. Anders is a translational researcher who is involved in the design of both clinical trials and preclinical, laboratory experiments within the Lineberger Cancer Center. She completed her Hematology-Oncology fellowship at Duke University (2005-2008) during which time she conducted a large-scale genomic analysis of breast cancers arising in younger women when compared to older counterparts. Her interesting results illustrating a unique biology uniting breast tumors arising in a younger host were recently published in the Journal of Clinical Oncology. During her fellowship, she was also instrumental in the design of several Phase II clinical trials for women who had developed brain metastasis from breast cancer - an aggressive complication of advanced disease for which systemic options and clinical trials are currently limited. She has dedicated her laboratory efforts toward understanding the complex biology/signaling pathways inherent to breast cancer-associated brain metastasis which the goal of moving her preclinical findings into the clinical arena. Working within the Perou laboratory, her preclinical studies include (1) a genomic analysis of human tissues in collaboration with the Department of Neurosurgery and UNC Pathology, (2) an investigation of breast cancer cell lines with predilection for central nervous system metastasis, and (3) conducting experiments with a validated brain metastasis animal model allowing the study of novel therapeutics, particularly nanoparticle anticancer agents capable of crossing the blood brain barrier, in collaboration with the Division of Pharmacotherapy and Experimental Therapeutics. She is also an active member in the UNC Multidisciplinary Breast Cancer Clinic treating and enrolling patients in Phase I - III clinical trials on a weekly basis. Finally, she is currently the recipient of the 2008 Cancer and Leukemia Group B Investigator's Award.
Recent Accomplishments and Honors
1. Cum Laude graduate
Brody School of Medicine, East Carolina University
1. American Society of Clinical Pathologists Award for Academic Excellence and Achievement,
2. Bakerman Scholarship Award for excellence in scholarship and service, 2001-2002
3. Honors in OB-GYN, Surgery, Family Medicine, Internal Medicine, Psychiatry, and Pediatrics,
4. Alpha Omega Alpha 2002
5. Janet M. Glasgow Memorial Achievement Citation, American Medical Womens Association,
1. Assistant Chief Resident, Veterans Affairs Hospital, Fall 2004
2. Institutional Committee of Graduate Medical Education (ICGME) Housestaff Representative,
3. Haskel-Schiff Award; Peer-selected for excellence in clinical medicine, 2005
4. Member, American Society of Clinical Oncology, 2005-present
5. Duke Translational Research in Oncology Training (T32) Grant Recipient, 2006-2008
6. Duke Hematology-Oncology Fellows Research Retreat Award, 2007
7. Duke Comprehensive Cancer Centers Annual Meeting Young Investigators Award
8. 2007 ASCO Foundation Merit Award
9. 2008 ASCO Foundation Merit Award
10. Cancer and Leukemia Group B (CALGB) Young Investigator Award, 2008-2009
11. Weatherspoon Family Brain Tumor Research Award, 2011
Vanderbilt University; Nashville, TN B.A. 1992-1996 Psychology/French
University of Pennsylvania; Philadelphia, PA Post-Bac. 1996-1997 Pre-medical studies
Brody School of Medicine, East Carolina University; Greenville, NC M.D. 1998-2002 Doctor of Medicine
Duke University Medical Center; Durham, NC Resident 2002-2005 Internal Medicine
Duke University Medical Center; Durham, NC Fellow 2005-2008 Hematology-Oncology
Morse MA, Hoeika A, Osada T, Niedzwiecki C, Marcom PK, Blackwell KL, Anders CK, et al. Long Term Disease-Free Survival and T Cell and Antibody Responses in Women with High-Risk HER2+ Breast Cancer Following Vaccination Against HER2. Journal of Translational Medicine 2007, 5:42 (06 Sep 2007).
Anders CK, Acharya CR, Hsu DS et al. Age-specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors. PLoS ONE 3(1): e1373 doi:10.1371/journal.pone.0001373; January 2, 2008.
Anders CK, Marcom PK, Peterson B et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Investigation, 2008; 26(3), 286-295.
Salter K, Perez B, Acharya C, Walters K, Redman R, Anguiano A, Garman K, Anders C, et al. An Integrated Approach to Prediction of Chemotherapeutic Response. PLoS ONE. 2008 Apr 2;3(4):e1908.
Acharya C, Anders C, Hsu D et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008 Apr 2;299(13):1574-87.
Anders CK, Hsu DS, Broadwater G et al. Young Age at Diagnosis Correlates with Worse Prognosis and Defines a Subset of Breast Cancers with Shared Patterns of Gene Expression. Journal of Clinical Oncology, 2008 Jul 10;26(20):3324-30.
Anders CK, Carey L. Understanding and Treating Triple-Negative Breast Cancer. Oncology (Williston Park). 2008 Oct;22(11):1233-9.
Anders CK and Johnson R, Litton J, Phillips M, Bleyer A. Breast Cancer before age 40 years. Semin Oncol. 2009 Jun;36 (3):237-49. Review . PMCID 2894028
Anders CK, Carey LA. Biology, Metastatic Patterns and Treatment of Triple Negative Breast Cancer. Clinical Breast Cancer. 2009 Jun 1, 9:S73-S81. PMCID pending
Anders CK, Winer EP, Ford J, Dent R, Silver D, Sledge GW, Carey LA. PARP: Inhibition: ?Targeted? Therapy for Triple Negative Breast Cancer. Clinical Cancer Research, 2010 Oct:16(19): 4702-4710.
Anders CK, Deal AM, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, and Carey LA. The Prognostic Contribution of Clinical Breast Cancer Subtype, Age and Race among Patients with Breast Cancer Brain Metastases. Cancer. 2010 Nov 29. [Epub ahead of print] PMID: 21117232.
Telephone: (919) 843-6814
Address: 170 Manning Drive, POB room 3119 Chapel Hill, NC 27599
Click here to update this profile